Osaic Holdings
LCTX icon

Osaic Holdings’s Lineage Cell Therapeutics LCTX Stock Holding History

Osaic Holdings’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.86K Sell
2,182
-36,108
-94% -$49.9K ﹤0.01% 7161
2026
Q1 		$60.5K Sell
38,290
-393
-1% -$663 ﹤0.01% 5059
2025
Q4 		$64.6K Sell
38,683
-46,113
-54% -$79.8K ﹤0.01% 5058
2025
Q3 		$123K Buy
84,796
+3,319
+4% +$3.93K ﹤0.01% 4613
2025
Q2 		$73.6K Sell
81,477
-15,775
-16% -$9.36K ﹤0.01% 4754
2025
Q1 		$43.8K Buy
97,252
+40,516
+71% +$23.8K ﹤0.01% 4821
2024
Q4 		$28.4K Sell
56,736
-7,315
-11% -$5.37K ﹤0.01% 5106
2024
Q3 		$58.1K Buy
64,051
+16,912
+36% +$15.7K ﹤0.01% 4639
2024
Q2 		$47K Buy
47,139
+45,052
+2,159% +$49.8K ﹤0.01% 4725
2024
Q1 		$3.09K Sell
2,087
-106
-5% -$120 ﹤0.01% 6304
2023
Q4 		$2.39K Sell
2,193
-44,178
-95% -$48.4K ﹤0.01% 6476
2023
Q3 		$54.7K Sell
46,371
-394
-0.8% -$536 ﹤0.01% 4942
2023
Q2 		$65.9K Buy
46,765
+81
+0.2% +$112 ﹤0.01% 4752
2023
Q1 		$70K Hold
46,684
– – ﹤0.01% 4728
2022
Q4 		$54.9K Buy
46,684
+44,400
+1,944% +$56K ﹤0.01% 4863
2022
Q3 		$2K Hold
2,284
– – ﹤0.01% 6786
2022
Q2 		$3K Hold
2,284
– – ﹤0.01% 6731
2022
Q1 		$3K Hold
2,284
– – ﹤0.01% 6739
2021
Q4 		$5K Sell
2,284
-89
-4% -$208 ﹤0.01% 6634
2021
Q3 		$6K Sell
2,373
-400
-14% -$1.03K ﹤0.01% 6446
2021
Q2 		$13K Sell
2,773
-3,123
-53% -$8.08K ﹤0.01% 5909
2021
Q1 		$13K Buy
5,896
+3,580
+155% +$8.6K ﹤0.01% 5737
2020
Q4 		$4K Sell
2,316
-698
-23% -$976 ﹤0.01% 5856
2020
Q3 		$3K Buy
3,014
+19
+0.6% +$17 ﹤0.01% 5733
2020
Q2 		$2K Buy
2,995
+134
+5% +$118 ﹤0.01% 5799
2020
Q1 		$2K Buy
+2,861
New +$2.85K ﹤0.01% 5692

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Osaic Holdings's LCTX Position: Q2 2026 in Review

Osaic Holdings reduced its Lineage Cell Therapeutics (LCTX) stake by 94% in Q2 2026, selling an estimated $49.9K and leaving 2,182 shares worth $2.86K. The position accounts for ﹤0.01% of the portfolio, ranked #7161.

Osaic Holdings first reported a position in LCTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $123K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Osaic Holdings held 2,182 shares of Lineage Cell Therapeutics worth $2.86K as of Q2 2026.
  • Osaic Holdings sold 36,108 Lineage Cell Therapeutics shares in Q2 2026, an estimated $49.9K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7161 holding.
  • Osaic Holdings first reported a position in Lineage Cell Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Lineage Cell Therapeutics position peaked at $123K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.